Atom Therapeutics and Evopoint Biosciences Cross-Claim RMB 50 Million in Trade Secret Dispute as Both Pursue IPOs
On March 20, 2026, Atom Therapeutics Co., Ltd. disclosed in its Hong Kong Stock Exchange listing application that it is embroiled in a high-stakes intellectual property dispute with Evopoint Biosciences Co., Ltd., involving competing claims of trade secret misappropriation and malicious litigation.

